Tobin Schilke
CIK 1678984 · Chief Financial Officer · last filed 2026-03-04
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.69M
Companies
3
Total Filings
54
Lifetime Open-Market Net
-$2.43M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CRNX | Chief Financial Officer | 78,121 | $34.47 | $2.69M | -$266.3K | 3 | 2026-03-04 |
| Revance Therapeutics, Inc. (RVNC) Delisted | CFO | 0 | $3.65 | $0 | -$2.07M | 43 | 2025-02-06 |
| Achaogen, Inc. (AKAO) Delisted | Chief Financial Officer | 48,046 | — | — | -$100.1K | 8 | 2018-06-28 |
Recent Filings · Page 2 of 6
54 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-01-03 | Revance Therapeutics, Inc. (RVNC) Delisted | Grant (A) | +434 | $3.2K | EDGAR |
| 2023-08-15 | Revance Therapeutics, Inc. (RVNC) Delisted | Mixed | +11,405 | -$212.1K | EDGAR |
| 2023-07-05 | Revance Therapeutics, Inc. (RVNC) Delisted | Mixed | −932 | -$30.6K | EDGAR |
| 2023-06-05 | Revance Therapeutics, Inc. (RVNC) Delisted | Sell (S) | −3,201 | -$98.1K | EDGAR |
| 2023-05-16 | Revance Therapeutics, Inc. (RVNC) Delisted | Mixed | +20,948 | -$739.3K | EDGAR |
| 2023-05-02 | Revance Therapeutics, Inc. (RVNC) Delisted | Sell (S) | −3,201 | -$101.5K | EDGAR |
| 2023-04-04 | Revance Therapeutics, Inc. (RVNC) Delisted | Sell (S) | −3,201 | -$102.9K | EDGAR |
| 2023-03-17 | Revance Therapeutics, Inc. (RVNC) Delisted | Tax (F) | −3,739 | -$114.6K | EDGAR |
| 2023-03-09 | Revance Therapeutics, Inc. (RVNC) Delisted | Mixed | +23,832 | -$584.9K | EDGAR |
| 2023-03-02 | Revance Therapeutics, Inc. (RVNC) Delisted | Sell (S) | −3,201 | -$107.2K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.